Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
This benefited companies like Purdue Pharma, the maker of OxyContin widely blamed for exacerbating the opioid epidemic in the U.S.
Simplified Text
Lobbying benefited Purdue Pharma maker of OxyContin.
Confidence Score
0.900
Claim Maker
The author
Context Type
News Article
Context Details
{
    "impact": "Exacerbating opioid epidemic",
    "company": "Purdue Pharma",
    "product": "OxyContin"
}
Subject Tags
Purdue Pharma OxyContin Opioid Epidemic
UUID
9fdb383d-9d8a-488f-9600-aacbd77844ae
Vector Index
✗ No vector
Created
September 12, 2025 at 1:01 AM (1 day ago)
Last Updated
September 12, 2025 at 1:01 AM (1 day ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://news.ufl.edu/2025/04/charity-lobbying/
Charities spend big to defend their board’s corporate agendas, new study reveals
Pending
News
11 claims 🔥
1 day ago
https://news.ufl.edu/2025/04/charity-lobbying/

A study reveals charities with corporate board members spend $130,000 annually lobbying for connected companies. This quid pro quo arrangement raises concerns about political influence, though it remains legal.

Charity
Lobbying
Corporate Influence
Political Influence
Nonprofit
Research
Governance

Similar Claims (0)

Other claims identified as semantically similar to this one.

No similar claims found

This claim appears to be unique in the system.

Claim Management System - MVP